MarketCap
Facebook
X
Telegram
Puma Biotechnology EV/EBITDA Ratio | PBYI
Annual EV/EBITDA Ratio Puma Biotechnology
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9.01 | 4.64 | 8.72 | 8.89 | 24.2 | -23.4 | -11.7 | -12.2 | -8.32 | -3 | -5.47 | -44.4 | -64.7 | -5.25 | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 24.2 | -64.7 | -8.8 |
EV/EBITDA Ratio of other stocks in the Biotechnology industry
| Issuer | EV/EBITDA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Cyclacel Pharmaceuticals
CYCC
|
0.257 | - | -5.98 % | $ 34.1 M |  USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
0.257 | - | -4.36 % | $ 27 M | USA |
 |
Diffusion Pharmaceuticals
DFFN
|
0.127 | - | 11.68 % | $ 8.97 M | USA |
 |
Eloxx Pharmaceuticals
ELOX
|
-11 | - | -5.68 % | $ 8.28 M | USA |
 |
Enochian Biosciences
ENOB
|
-2.01 | - | - | $ 40.5 M | USA |
 |
Esperion Therapeutics
ESPR
|
19.2 | - | - | $ 661 M | USA |
 |
Evofem Biosciences
EVFM
|
26.3 | - | 7.55 % | $ 38.1 M | USA |
 |
Eyenovia
EYEN
|
-0.0912 | - | 49.81 % | $ 13.2 M | USA |
 |
FibroGen
FGEN
|
-1.49 | - | - | $ 889 M | USA |
 |
Homology Medicines
FIXX
|
-1.65 | - | 0.77 % | $ 53.4 M | USA |
 |
Amicus Therapeutics
FOLD
|
121 | - | - | $ 4.47 B | USA |
 |
Frequency Therapeutics
FREQ
|
-0.342 | - | - | $ 528 M | USA |
|
Galecto
GLTO
|
1.13 | - | - | $ 762 M |  Danmark |
 |
GlycoMimetics
GLYC
|
1.15 | - | 9357.83 % | $ 1.01 B | USA |
 |
Graybug Vision
GRAY
|
-0.378 | - | -11.23 % | $ 9.65 M | USA |
|
Galera Therapeutics
GRTX
|
2.25 | - | -32.59 % | $ 7.61 M | USA |
 |
Happiness Biotech Group Limited
HAPP
|
0.512 | - | 1.35 % | $ 17.8 M |  China |
 |
Novavax
NVAX
|
6.05 | $ 9.78 | -8.22 % | $ 1.58 B | USA |
 |
Hepion Pharmaceuticals
HEPA
|
0.252 | - | -18.79 % | $ 39.3 K | USA |
 |
Hoth Therapeutics
HOTH
|
-0.517 | - | - | $ 18.8 M | USA |
 |
IMARA
IMRA
|
0.69 | - | 15.96 % | $ 663 M | USA |
 |
KalVista Pharmaceuticals
KALV
|
-8.5 | - | - | $ 1.45 B |  Britain |
 |
KemPharm
KMPH
|
-1.15 | - | -0.34 % | $ 200 M | USA |
 |
Kezar Life Sciences
KZR
|
0.343 | - | - | $ 53.3 M | USA |
 |
Lixte Biotechnology Holdings
LIXT
|
-4.63 | - | - | $ 63.4 M | USA |
 |
Magenta Therapeutics
MGTA
|
0.0763 | - | -7.74 % | $ 41.6 M | USA |
 |
NovaBay Pharmaceuticals
NBY
|
-75.8 | - | - | $ 11.3 M | USA |
 |
NeuroBo Pharmaceuticals
NRBO
|
0.328 | - | 0.43 % | $ 12 M | USA |
 |
OncoCyte Corporation
OCX
|
-0.933 | - | 17.22 % | $ 355 K | USA |
 |
Onconova Therapeutics
ONTX
|
-0.417 | - | -0.47 % | $ 21 M | USA |
 |
Opthea Limited
OPT
|
-1.34 | - | - | $ 1.2 B |  Australia |
 |
Verastem
VSTM
|
-2.28 | $ 9.38 | -4.82 % | $ 650 M | USA |
|
BiomX
PHGE
|
-0.109 | $ 1.85 | 14.2 % | $ 3.02 M |  Israel |
 |
Pieris Pharmaceuticals
PIRS
|
0.684 | - | -15.58 % | $ 1.22 B |  Germany |
 |
Plus Therapeutics
PSTV
|
-2.06 | - | - | $ 301 M | USA |
 |
Pluristem Therapeutics
PSTI
|
0.144 | - | -1.9 % | $ 33.3 M | Israel |
 |
Qualigen Therapeutics
QLGN
|
1.46 | - | 5.59 % | $ 1.16 M | USA |
|
Qilian International Holding Group Limited
QLI
|
-2.89 | - | -6.08 % | $ 184 M | China |
 |
Cassava Sciences
SAVA
|
-0.543 | - | - | $ 110 M | USA |
 |
Selecta Biosciences
SELB
|
-2.11 | - | -8.69 % | $ 126 M | USA |
 |
Sangamo Therapeutics
SGMO
|
-1.19 | - | - | $ 50.4 M | USA |
 |
Salarius Pharmaceuticals
SLRX
|
0.44 | - | - | $ 2.64 M | USA |
 |
Sensei Biotherapeutics
SNSE
|
-1.23 | - | - | $ 17.5 M | USA |
 |
Sonnet BioTherapeutics Holdings
SONN
|
0.0646 | - | - | $ 826 K | USA |
 |
Synthetic Biologics
SYN
|
-0.409 | - | 1.32 % | $ 16.2 M | USA |
 |
Synlogic
SYBX
|
3.66 | - | - | $ 7.07 M | USA |
 |
Virios Therapeutics, LLC
VIRI
|
-0.313 | - | 2710.01 % | $ 72.9 M | USA |
 |
Vallon Pharmaceuticals
VLON
|
0.465 | - | -6.47 % | $ 5.76 M | USA |
 |
Vaxart
VXRT
|
29.7 | - | -25.06 % | $ 46.3 M | USA |
 |
XOMA Corporation
XOMA
|
29 | - | - | $ 485 M | USA |